Eikon Therapeutics to present seven abstracts at ESMO 2026
Eikon Therapeutics (Nasdaq: EIKN) has published full-text abstracts for seven presentations covering its four clinical-stage oncology candidates ahead of the European Society for Medical Oncology (ESMO) Congress in Madrid, which opens on 23 October 2026. The slate spans updated Phase 2 data, initial combination-therapy readouts and early pharmacokinetic findings, making it among the more substantive pipeline showcases the Millbrae, California-based company has mounted to date.
Roger Perlmutter, chief executive and board chair, said the seven abstracts reflect "new clinical findings and continued progress" across the pipeline, with Eikon scientists planning to discuss results directly with the oncology community in Spain. The company declined to release numerical data ahead of the formal presentations.
The pipeline on show
The most advanced data expected at the congress relates to EIK1001, a TLR7/8 dual-agonist being evaluated in combination with pembrolizumab and histology-appropriate chemotherapy in stage 4 NSCLC. The TeLuRide-005 abstract scheduled for 26 October will include updated pooled results and, notably, data from the squamous histology cohort, a subgroup that has historically been harder to treat within the NSCLC landscape. A second EIK1001 abstract outlines the design of TeLuRide-008, a planned Phase 2/3 study in the same indication, suggesting Eikon is already scoping a registration-enabling programme.
EIK1003, described as a highly selective, non-brain-penetrant PARP1 inhibitor, will feature in two abstracts on 23 October: one covering monotherapy and paclitaxel combination data in advanced solid tumours, and a second presenting initial results from a combination with abiraterone in metastatic prostate cancer. The prostate cancer data are framed as initial findings, so granular efficacy numbers are unlikely to be mature.
EIK1004 is positioned as the CNS-penetrant counterpart to EIK1003, designed to reach brain metastases where standard PARP inhibitors cannot. Its first-in-human Phase 1/2 data in patients with homologous recombination repair mutations will also be presented on 23 October. Finally, EIK1005, a Werner helicase inhibitor being studied in microsatellite-instable and mismatch-repair deficient tumours, contributes two abstracts: a safety and pharmacokinetics analysis and a trial-in-progress ePoster for a combination study with pembrolizumab.
Market and competitive context
The PARP inhibitor field is crowded, with approved agents from AstraZeneca, GSK and Pfizer commanding significant market share across breast, ovarian and prostate cancer indications. Eikon's strategy of developing two isoform-selective PARP1 inhibitors with distinct CNS-penetrance profiles reflects a broader industry effort to differentiate from first-generation pan-PARP agents, which carry substantial haematological toxicity. Whether selectivity and CNS penetrance translate into meaningful clinical advantages over established options remains to be demonstrated in randomised data.
The TLR7/8 agonist space is comparatively less developed in NSCLC, with pembrolizumab combinations being a logical framework given the established role of PD-1 blockade in the indication. Eikon's TeLuRide programme will need to show a signal that justifies the added complexity of a triple-combination regimen before regulators or payers are likely to view it as a viable standard-of-care option.
Investors tracking Eikon will focus on whether the ESMO presentations include response rates and durability data sufficient to derisk the Phase 2/3 pivot implied by the TeLuRide-008 trial-in-progress abstract. The congress presentations begin 23 October; full data will be made available following the sessions.